Keros Therapeutics Halts Treatment In 3.0 Mg/Kg and 4.5 Mg/Kg Treatment Arms In Ongoing TROPOS Trial Over Safety Concerns
Keros Therapeutics Halts Treatment In 3.0 Mg/Kg and 4.5 Mg/Kg Treatment Arms In Ongoing TROPOS Trial Over Safety Concerns
Keros Therapeutics, Inc. ("Keros" or the "Company") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta ("TGF-ß") family of proteins, today announced that it has voluntarily halted dosing in the 3.0 mg/kg and 4.5 mg/kg treatment arms in the ongoing TROPOS trial, a Phase 2 clinical trial of cibotercept (KER-012) in combination with background therapy in patients with pulmonary arterial hypertension ("PAH"), based on a safety review due to the unanticipated observation of pericardial effusion adverse events in the trial.
Keros Therapeutics, Inc. （"Keros" 或 "公司"）（納斯達克：KROS）是一家專注於開發和商業化新型治療藥物的臨床階段生物製藥公司，旨在治療與轉化生長因子-β（"TGF-ß"）家族蛋白功能失調信號相關的廣泛患者群體。今天宣佈，根據安全性審查，因在試驗中意外觀察到心包積液不良事件，該公司已自願停止在進行中的TROPOS試驗中3.0 mg/kg和4.5 mg/kg的治療組進行給藥。TROPOS試驗是一項針對與背景治療聯合使用的cibotercept（KER-012）的Ⅱ期臨床試驗，研究對象爲患有肺動脈高壓（"PAH"）的患者。
